Skip to main content
. 2025 Jan 7;31(1):98561. doi: 10.3748/wjg.v31.i1.98561

Table 3.

Summary of statistical results for the Control, Kangfuxin solution-treated, and PDNN-treated groups


Control
KFX
PDNN
P value
Weight loss, kg 4.08 ± 0.69 1.98 ± 0.79b 2.03 ± 1.07b 0.011
Dysphagia score 3.50 ± 0.58 1.75 ± 0.50b 1.25 ± 0.96a 0.004
Esophageal stricture rate 87.68 ± 1.90 59.67 ± 5.05a 53.90 ± 6.29a < 0.001
Number of inflammatory cells 1976.25 ± 116.39 950.25 ± 276.92a,e 1651.50 ± 153.97c < 0.001
Number of fibroblasts 5736.25 ± 691.56 1537.00 ± 118.89a, f 710.00 ± 347.14a < 0.001
Fibrosis area ratio 66.20 ± 8.95 34.63 ± 3.64a,f 23.47 ± 2.65a < 0.001
Thickness of submucosal fibrosis, um 853.93 ± 20.16 672.20 ± 28.69a,d 512.83 ± 42.73a < 0.001
a

P < 0.001 vs the control group.

b

P < 0.01 vs the control group.

c

P < 0.05 vs the control group.

d

P < 0.001 vs the prednisolone (PDNN) group.

e

P < 0.01 vs the PDNN group.

f

P < 0.05 vs the PDNN group.

Data are presented as mean ± SE. KFX: Kangfuxin solution; PDNN: Prednisolone.